Characteristics | Survivors | Deceased | p | Multivariate analysis | |
---|---|---|---|---|---|
(n = 1180) | (n = 345) | Cause-specific hazard [95% CI] | p | ||
Age (years) | 67 [59–75] | 68 [60–74] | 0.7 | ||
Male gender | 714 (60.5) | 230 (66.7) | 0.17 | ||
ICU admission | |||||
2007–2012 | 505 (39.1) | 147 (43.6) | 0.13 | ||
2013–2018 | 675 (60.9) | 198 (57.4) | |||
Type of cancer | < 0.001 | ||||
Lung | 257 (21.8) | 122 (35.4) | |||
Gastrointestinal | 298 (25.3) | 99 (28.7) | |||
Urologic | 275 (23.3) | 39 (11.3) | |||
Cutaneous | 23 (2.0) | 3 (0.9) | |||
Breast | 123 (10.4) | 30 (8.7) | |||
Lung cancer | 257 (21.8) | 122 (35.4) | < 0.001 | 1.32 [1.04–1.66] | 0.02 |
Non-lung cancer | 923 (78.2) | 223 (64.6) | – | – | |
Stage | < 0.001 | ||||
Localized | 314 (26.6) | 58 (16.8) | – | – | |
Advanced | 258 (21.9) | 56 (16.2) | – | – | |
Metastatic | 597 (50.6) | 227 (65.8) | 1.78 [1.38–2.30] | < 0.001 | |
Status | < 0.001 | ||||
Newly diagnosed | 314 (26.6) | 105 (30.4) | – | – | |
Partial remission | 259 (21.9) | 41 (11.9) | – | – | |
Complete remission | 182 (15.4) | 38 (11.0) | – | – | |
In progression | 384 (32.5) | 156 (45.2) | 1.62 [1.28–2.05] | < 0.001 | |
Treatment in the past 3 months | |||||
Chemotherapy | 575 (48.7) | 181 (52.5) | 0.215 | – | – |
Surgery | 183 (15.5) | 29 (8.4) | 0.003 | 0.68 [0.45–1.01] | 0.05 |
Immunotherapy/targeted therapy | 129 (10.9) | 46 (13.3) | 0.256 | – | – |
SOFA score | 5 [4–7] | 8 [5–12] | < 0.001 | 1.02 [1.01–1.03]a | < 0.001 |
Organ failure supports | |||||
Invasive mechanical ventilation | 338 (28.6) | 290 (84.1) | < 0.001 | 3.73 [2.45–5.69] | < 0.001 |
Non-invasive mechanical ventilation | 142 (12.0) | 21 (6.1) | 0.002 | 2.87 [1.65–5.01] | < 0.001 |
Inotropes/vasopressors | 265 (22.5) | 247 (71.6) | < 0.001 | 1.74 [1.29–2.34] | < 0.001 |
Renal replacement therapy | 144 (12.2) | 115 (33.3) | < 0.001 | 1.33 [1.03–1.70] | 0.03 |
Admission patterns | |||||
Non-specific complications | 729 (61.8) | 224 (64.9) | 0.318 | – | – |
Specific complications | 313 (26.5) | 96 (27.8) | 0.681 | 1.33 [1.04–1.72] | 0.007 |
Adverse event complications | 138 (11.7) | 25 (7.2) | 0.024 | – | – |
Drug-related adverse event | 51 (4.3) | 6 (1.7) | 0.039 | ||
Procedural adverse event | 87 (7.4) | 19 (5.5) | 0.281 |